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Abstract
Erythroid differentiation of normal human hematopoietic progenitor cells was drastically inhibited by phorbol ester,
 .  .12-myristate 13-acetate PMA , an agent known to activate the class of serine-threonine kinases, protein kinase C PKC .
This inhibition was accompanied by augmented megakaryocytic differentiation as demonstrated by expression of megakary-
ocyte-specific mRNAs and proteins. These effects of PMA were reversed by two specific antagonists of PKC. Analysis of
single colonies transferred from cultures not containing PMA to PMA-containing cultures indicated that, in this system,
PMA exerts megakaryocytic differentiating activity directly on cells which may have already initiated a progression toward
the erythroid pathway of differentiation. These results suggest that modulation of PKC activity plays a role in erythroid and
megakaryocytic differentiation, and may constitute an important selective signal between these pathways during normal
blood cell development. q 1997 Elsevier Science B.V.
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1. Introduction
Coordinate expression of genes that specify the
terminal differentiation phenotype of hematopoietic
cells is at least partially controlled by the interactions
of hematopoietic growth factors and cytokines with
 w x.their cognate cell surface receptors reviewed in 1,2 .
Considerable progress has been achieved in recent
years in understanding the specific signals induced by
various cytokines upon binding to their receptors. As
a result of this work, it is becoming apparent that
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cytokines involved in the regulation of different
hematopoietic lineages often act through common
 w x.signalling pathways reviewed in 3 . The presence
of common signalling pathways among receptors
specifying different hematopoietic lineages raises an
important question that remains largely unresolved:
what is the mechanism of lineage determination dur-
ing hematopoiesis?
Erythroid and megakaryocytic pathways of differ-
entiation lead to distinctly different cell types,
erythrocytes and platelets. However, it has been
shown that differentiation pathways for those two cell
types are closely related. Moreover, it has been hy-
pothesized that there may exist a common progenitor
 . w xEM for erythroid and megakaryocytic cells 4,5 .
Some evidence of commonality includes, but is not
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 .limited to: i Erythroid and megakaryocytic cells
express common transcription factors, GATA-1,
w x  .  .GATA-2, and SCL 6–8 . ii Erythropoietin Epo ,
the main regulator of erythroid differentiation, has
been implicated in the regulation of megakaryocy-
w xtopoiesis 9,10 , and the megakaryocyte-specific
 .growth factor, thrombopoietin Tpo , was shown to
w xaugment proliferation of erythroid progenitors 11 .
 .iii Epo and Tpo activate closely related or identical
signal transduction pathways upon binding to their
w x  .corresponding cell-surface receptors 12,13 . iv
Large chronic doses of Epo cause thrombocytopenia
in mice, and, conversely, acute thrombocytopenia
causes increased thrombocytopoiesis and decreased
w x  .erythropoiesis 14 . v Numerous human cell lines
derived from various forms of leukemias co-express
erythroid and megakaryocytic markers and can be
induced to differentiate toward erythroid or
megakaryocytic pathway by varying culture condi-
w xtions 5,15–17 .
To account for the differences between erythroid
and megakaryocytic cells, one may postulate that at a
certain stage of maturation, a putative erythroid-
megakaryocytic progenitor receives regulatory
 .signal s unique to erythroid or megakaryocytic lin-
 .eage, and that this signal s determine the differentia-
tion fate of the developing progenitor cell. Although
 .the nature of this signal s remains unknown, the
results obtained w ith hum an bipotential
erythroidrmegakaryocytic cell lines may be of rele-
vance. When grown under standard conditions, some
w xof these cells express predominantly erythroid 15,16
w xand some predominantly megakaryocytic 17,18
markers. Certain inducers, such as hemin, further
enhance the erythroid characteristics of these cells
w x16 . On the other hand, treatment with PKC activa-
tors, tumor promoting phorbol esters such as PMA
w x19,20 , leads to a drastic down-regulation of the
erythroid and up-regulation of the megakaryocytic
w xphenotype of these cells 17,18,21,22 . This response
to phorbol ester suggests that, at least in the leukemic
cell line systems, modulation of PKC activity may be
involved in selectivity between erythroid and
megakaryocytic pathways. However, no information
is available at present as to the possible role of PKC
signalling in erythroid and megakaryocytic differenti-
ation of normal human cells.
To investigate this question, we examined the
effect of phorbol ester on normal human hemato-
poietic progenitor cells undergoing erythroid differen-
tiation in vitro in the presence of Epo. The results of
this work show that human progenitor cells from
normal adult peripheral blood, or from umbilical cord
blood, behave similarly to the leukemic cell lines in
their down-regulation of erythroid and up-regulation
of megakaryocytic phenotype in the presence of PMA.
Moreover, these effects of PMA are counteracted by
two specific antagonists of PKC. Our results also
suggest that suppression of erythroid and induction of
megakaryocytic genes may take place within a popu-
lation of cells that had already begun erythroid differ-
entiation prior to addition of PMA. Based on these
findings, a model that can account for selectivity
between erythroid and megakaryocytic lineages is
proposed.
2. Materials and methods
2.1. Cell purification and culture
 .Peripheral blood mononuclear cells PBMC were
prepared using fractionation through Ficoll-Paquew
 .Pharmacia LKB, Uppsala, Sweden of heparinized
blood obtained from normal adult volunteers. Umbili-
cal cord blood was obtained from normal deliveries
after informed consent Meriter Hospital, Madison,
.WI . Cord blood mononuclear cell fraction from Fi-
coll-Paquew was enriched for CD34q progenitor cell
 .using Cepratee LC CD34 cell separation system
 .CellPro, Inc., Bothel WA following the manufac-
turer’s instructions. In multiple experiments the
CD34q progenitor enriched populations obtained us-
ing this system contained from 30% to 60% of
CD34q cells, as determined by flow cytometric anal-
ysis of the purified cell populations labeled with
anti-CD34 antibody anti-HPCA-2, Becton Dickin-
.son, Mountain View, CA .
Suspension and methylcellulose cultures were es-
w xtablished using described procedures 23 . For the
methylcellulose cultures, each 35 mm culture dish
was plated with 4–5=105 total PBMC, or 5=103
cells from the CD34q progenitor enriched fraction in
2 ml of culture medium. The plating efficiency was
0.03–0.1% for PBMC populations and 2–5% for
CD34q progenitor enriched cell populations. The
culture medium consisted of 10% phytohemagglu-
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tinin-stimulated leukocyte conditioned medium pre-
w x.pared as described in 23 , 30% fetal calf serum
 .FCS, Gibco BRL, Grand Island, NY , 1% bovine
 .serum albumin BSA, Sigma, St. Louis, MO , 50
mM 2-mercaptoethanol, antibiotics, 0.9% methylcel-
lulose, and Iscove’s modified Dulbecco’s media
 .IMDM, Gibco BRL , and 2 Urml of human recom-
 .binant Epo R&D systems, Minneapolis, MN . For
the suspension cultures, 1=105 cells from the
CD34q progenitor enriched fraction was added per
well to a 6-well tissue culture plate in 6 ml of the
above culture medium without methylcellulose. The
cultures were incubated at 378C in a humidified
atmosphere of 5% CO . In PMA-containing cultures,2
 .PMA in dimethylsulfoxide, DMSO was added to a
final concentration of 100 nM. PMA or DMSO
. vehicle was added to the cultures at time zero when
.the cultures were established or at designated later
times. In cultures containing PKC antagonists, bisin-
 .dolylmaleimide I GF-109203X and bisindolyl-
maleimide IX Ro 31-8220; both from LC Laborato-
. ries, Woburn, MA , the antagonists dissolved in
.DMSO were added to the cultures 30 min prior to
addition of PMA.
2.2. Immunofluorescence labeling and flow cytometry
analysis
Cells from the suspension cultures were harvested,
 .washed in phosphate buffered saline PBS contain-
ing 0.1% BSA and 0.1% sodium azide, counted and
 .reacted with fluorescein isothiocyanate FITC -
 .labeled anti-glycophorin GPA and phycoerythrin
 . PE -labelled anti-CD41 antibodies both from Coul-
.ter Immunology, Hialeah, FL for 30 min on ice in
the dark. The labelled cells were washed in
PBSr0.1% BSAr0.1% sodium azide, and analyzed
on a FACScan with the Lysis II software program
 .Becton Dickinson . For each antibody, the appropri-
ate isotype controls were included in every experi-
ment. Dead cells were excluded from the analysis by
gating on forward scatter and propidium iodide
 .Sigma exclusion.
2.3. Immunohistochemistry
Cytospins of 5=104 cells from the suspension
 .cultures were prepared on poly-L-lysine Sigma -
covered microscope slides, and the cells were incu-
bated with a mouse monoclonal anti-human platelet
 .glycoprotein IIIa GPIIIa monoclonal antibody, clone
 .Y2r51 DAKO Corp., Glostrup, Denmark for 10
min. Final concentration of the antibody was 1
mgrml. Irrelevant antibody was included as a nega-
tive control in every experiment. The primary anti-
body was detected using streptavidine-biotin detec-
 .tion DAKO LSAB2 kit, peroxidase following man-
ufacturer’s instructions. To visualize the cells, they
were counterstained with Mayer’s hematoxylin nu-
 .clear stain Sigma .
[3 ]2.4. H -thymidine uptake and apoptosis analysis
w3 xFor H -thymidine uptake assay, the Epo-contain-
ing suspension cultures were established in 24-well
culture plates with 1=104 cellsrwell in 2 ml of
culture medium. All measurements were performed
in duplicates. After 11 days of culture at 378C, 5%
CO , PMA was added to the half of the wells. The2
incubation was continued for another 28 or 52 h, at
w3 xwhich time the cells were pulsed with H -thymidine
for 10 h 5 mCirwell, 20 Cirmmol, DuPont NEN,
.Wilmington, DE . The cells were centrifuged, the
medium was removed, and the pellets were treated
 .with 10% trichloracetic acid TCA for 10 min at
room temperature. The pellets were washed twice in
5% TCA, and resuspended in 0.1 N NaOH. 450 ml of
the lysate solution was mixed with 10 ml of Ecoscint
scintillation cocktail National Diagnostics, Atlanta,
.GA , and the radioactivity in the samples was deter-
mined using liquid scintillation analyzer Packard
.Instrument Co., Downers Grove, IL . Apoptosis anal-
ysis was carried out using a cell death detection
ELISA kit Boehringer Mannheim Biochemicals, In-
.dianapolis, IN following the manufacturer’s instruc-
tions. All measurements were performed in dupli-
cates.
2.5. Preparation of total cellular RNA
The cells were collected by centrifugation, and the
RNA was prepared using RNeasy total RNA purifica-
 .tion kit Qiagen, Chatsworth, CA using manufac-
turer’s instructions. To analyze tissue-specific mRNA
expression of cells from individual colonies, the
colonies were harvested from the culture dishes with
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drawn Pasteur pipettes while visualizing under a mi-
croscope. The colonies were transferred directly from
the pipettes into a lysis buffer containing E. coli
rRNA carrier, followed by RNA extraction, as de-
scribed above.
2.6. Re˝erse transcriptionrpolymerase chain reac-
( )tion RTrPCR analysis of RNA
To obtain cDNA preparations that were representa-
tive of the different RNA species from the cell
samples, random hexamer primers were used to prime
the RT reactions. With this approach, it was possible
 .to use the same RT reaction i.e., resultant cDNA’s
for the PCR amplifications with the different sets of
 .gene-specific primers Table 1 . The RT reactions
were carried out with Moloney murine leukemia virus
 .M-MLV Superscripte II reverse transcriptase
 .Gibco BRL following the manufacturer’s instruc-
tions. To analyze relative expression of different
tissue-specific mRNAs, the amount of cDNA used
for PCR was normalized based on the signal from the
ubiquitously expressed ribosomal protein RPL19
w xmRNA 24 . As a negative control, one sample con-
taining the RT cDNA product of E. coli rRNA was
included with each set of the gene-specific primers in
all PCR experiments. Positions of the gene-specific
primers for the PCR analysis were chosen so that the
RNA sequence spanned an intron in the tested gene,
and thus the cDNA-specific PCR product would be
of lower molecular weight than the genomic DNA-
specific product originating from possible traces of
.genomic DNA in the RNA preparations . The PCR
amplifications were conducted in a DNA thermal
cycler model 480, Perkin-Elmer Cetus, Norwalk,
.CT using a fraction of the cDNA product of the RT
reaction and 2.5 u of Taq DNA polymerase Pro-
.mega Corporation, Madison, WI according to the
manufacturer’s protocol, with 20 pmol of the two
 .gene-specific primers Table 1 in a reaction volume
of 50 ml. The number of cycles varied between 25
and 35, depending on the particular mRNA abun-
dance. For the initial experiments, the PCRs were
conducted at two or three different cycle schedules,
and with different quantities of the input cDNA. The
number of cycles and the amount of cDNA was then
chosen in such a way as to select PCR conditions on
the linear portion of the reaction curve avoiding
‘saturation effects’ of the PCR, and hence allowing
semi-quantitative comparisons between the samples.
3. Results
3.1. Phorbol ester down-regulates erythroid and up-
regulates megakaryocytic gene expression in human
progenitor cell cultures
To ascertain the effect of phorbol ester on human
erythroid and megakaryocytic differentiation, human
Table 1
Primers used for PCR amplifications a
X X b .Gene ref. 5 -Primer 3 -Primer Product Distance from
cfirst ATG
w xg-globin 31 CTCGCTTCTGGAACGTCTGA GGTGCTTTATGGCATCTCCCAAGGA 286 y48
w xb-globin 32 GACACAACTGTGTTCACTAGCA TGCAGCTTGTCACAGTGCAGCT 329 y38
w xGPA 33 ATCTTTGTATTACTATTCTCAGC AACTTAAAGGCACGTCTGTGTC 400 q16
w xEpoR 34 ACTACAGCTTCTCCTACCAGC CCGAGACGTCCACCTCGTAGC 319 q227
w xGATA-1 35 TTAGCCACCTCATGCCTT GAGACTTGGGTTGTCCAG 195 q1127
w xPDGF B 36 CTTTATGAGATGCTGAGTGA CGGCACTGCACGTTGCGGTT 349 q38
w xGPIIIa 37 CTCGCTGTGACCTGAAGGAGA AAACATGGGCAAGCAGGTGG 450 q183
w xGP1ba 38 GCCAGCCACCTAGAAGTGAACT GAAGGGTGTCGAGATTCTCCAG 505 q75
w xPF-4 39 ACTGAGCACTGAGATCCTGCTG CAGCTAGTAGCTAACTCTCCAA 345 y38
w xMYP 40 TACAAGGAGCGGCGGGAAAG AGCGCACGATCTCGTTGAG 481 q228
w xRPL19 30 CTGAAGGTCAAAGGGAATGTG GGACAGAGTCTTGATGATGATCTC 194 q372
a Sequence of primers in 5X to 3X direction.
b Size of PCR product in base pairs.
c  . X XDistance in base pairs of first ATG codon from 5 terminus of 5 primer.
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hematopoietic progenitor cells were exposed to PMA
in the presence of Epo in methylcellulose or liquid
suspension cultures. Two different sources of progen-
 .itor cells were used for these experiments: i human
umbilical cord blood mononuclear cells that were
further fractionated to enrich for CD34 antigen-ex-
pressing cells CD34 is a marker of early human
w x.  .progenitor cells 25 , and ii unfractionated PBMC
from normal adults that contain a small proportion of
progenitor cells. The PBMC and CD34q-enriched
cell populations behaved identically with respect to
their response to PMA, as assayed by RTrPCR
progenitor cell population in each experiment is
.specified in the figure legends . A scheme of a
typical experiment is shown in Fig. 1.
In methylcellulose colony assays the majority of
colonies that arose in the presence of Epo and in the
absence of PMA were of the classical erythroid type
 .Fig. 2 . Some macrophage, and granulocytermacro-
phage colonies were also obtained under these condi-
tions. The majority of the erythroid colonies observed
were of the mature erythroid burst-forming units
 .BFU-E -type, and were composed of large well
 .hemoglobinized clusters of 500–1000 cells Fig. 2 .
Some smaller erythroid colony-forming units CFU-
.E -type colonies composed of 25–100 cells were also
seen. Addition of PMA to the cultures on day 0
resulted in a complete inhibition of all colony forma-
tion. However, delaying addition of PMA until either
day 9 or 11 at this time the hemoglobinized imma-
ture erythroid colonies are easily distinguishable from
.other types of colonies resulted in a drastic reduction
in the level of hemoglobinization of the colonies as
they continued their development in the presence of
 .PMA Fig. 2 . The average size of the colonies
developing in the presence of PMA was also reduced
compared to colonies developing in the absence of
.PMA . The erythroid and megakaryocytic gene ex-
Fig. 1. Schematic representation of the experimental design of the
progenitor culture assays.
Fig. 2. Morphology of a typical day 20 erythroid colony from
Epo-containing cultures with or without PMA. Cultures were
established using PBMC. For experimental details see Section 2.
pression by the cells that developed in the absence
and in the presence of PMA was then examined using
RTrPCR, flow cytometry and immunohistochem-
istry.
The results of a representative RTrPCR analysis
that was reproduced in at least 5 more for some of
.the examined genes independent experiments is
shown in Fig. 3. In control cultures maintained in the
 .absence of PMA lanes 1–3 , the expression of sev-
 w x w xeral erythroid mRNAs g-globin 26 ; b-globin 27 ;
erythroid-specific surface glycoprotein, glycophorin
w x w xA, GPA 28 ; Epo receptor, EpoR 29 ; erythroid-
w x.specific transcription factor, GATA-1 30 was either
 .progressively induced b-globin, EpoR or remained
 .constant GATA-1, GPA . The only exception was
g-globin mRNA - its expression was reduced. The
reduction in g-globin mRNA expression with matura-
tion of erythroid cultures is to be expected, since it is
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known that expression of g-globin gene declines
w xduring erythroid differentiation 31 . The results in
Fig. 3 also show that in cultures without PMA,
GATA-1 mRNA is expressed earlier than EpoR
mRNA. In other experiments EpoR mRNA was de-
 .tected in day 9 cultures not shown ; nevertheless, the
pattern of developmental expression of EpoR mRNA
was always the same, in that in the absence of PMA
EpoR mRNA levels increased from day 9 to day 20
of culture. The expression of GATA-1 mRNA was
relatively unchanged during this period of time. Some
low level signal from megakaryocytic mRNAs was
also seen in the cultures without PMA, but this signal
did not increase as the cultures progressively ma-
tured.
 .When PMA was added on day 0 lane 6 , it
completely suppressed both erythroid and megakary-
ocytic mRNA expression as to be expected from the
Fig. 3. RTrPCR analysis of erythroid and megakaryocytic mR-
NAs expressed by the total cell population harvested from Epo-
containing methylcellulose cultures grown with or without PMA.
Cultures were established using PBMC. Lanes 1–3-no PMA,
cells harvested on days 9, 11, and 20, respectively. Lanes 4–6-
PMA added on days 9, 11, and 0, respectively, cells harvested on
day 20. Lane 7-negative control, E. coli rRNA. The identity of
the primers used for PCR, and the molecular weights of the PCR
products are defined in Table 1.
general inhibition of colony formation by PMA, see
.above . However, addition of PMA on days 9 or 11,
 .with harvest on day 20 lanes 4–5 , inhibited ery-
throid mRNA expression only partially. The results
of analysis of several megakaryocytic mRNAs in
these samples platelet derived growth factor B, PDGF
w x w xB 32 ; platelet glycoprotein Iba , GPIba 33 ; platelet
w xglycoprotein IIIa, GPIIIa 34 ; platelet factor 4, PF-4
w x.35 revealed that PMA acts as a strong stimulus for
increasing these mRNAs when addition of the agent
was delayed until days 9 or 11. Also, the activation
was somewhat stronger in the day 11 cells than in the
day 9 cells. Only very low levels of megakaryocytic
mRNA was detected when PMA was added on days
 .1, 3, and 5 not shown . Addition of PMA on day 13
resulted in a partial inhibition of the erythroid and
induction of the megakaryocytic mRNAs, but the
magnitude of both effects was smaller than in the day
 .11 culture not shown . Because addition of PMA on
day 11 resulted in the strongest induction of
megakaryocytic phenotype, this schedule of PMA
addition was used in all subsequent experiments.
It must be noted that not all megakaryocytic mark-
ers analyzed here are absolutely specific for
megakaryocytes; the GPIIIa, for example, is also
w xexpressed on endothelial cells 36 . However, the fact
that a constellation of 4 different markers was ex-
pressed by hematopoietic cells in the presence of
PMA makes it most likely that the cell population
under study has characteristics of megakaryocytes.
To determine whether the observed inhibition of
erythroid and induction of megakaryocytic mRNAs
also took place at the level of protein expression,
flow cytometry and immunohistochemical analysis of
suspension cultures established from CD34q progeni-
tor enriched cell populations was carried out. Results
of a typical flow cytometry analysis reproduced in
three independent experiments are shown in Fig. 4.
The cells were analyzed on day 19 of culture; GPA
was used as a representative erythroid, and CD41
 .platelet glycoprotein IIbrIIIa complex as a repre-
sentative megakaryocytic marker. The majority of
 .cells grown without PMA Fig. 4A were positive for
GPA; no cells in this population expressed CD41. On
the other hand, in the PMA-containing culture Fig.
.4B , the level of GPA expression and the number of
cells expressing GPA was drastically reduced as
compared to the cultures lacking PMA; furthermore,
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a considerable number of cells initiated CD41 expres-
sion. A small number of cells stained positive for
both GPA and CD41; these may represent double
positive cells, or cell aggregates, which were some-
times detected in immunohistochemical staining ex-
 .periments see below .
The results of immunohistochemical staining of
 .the progenitor cultures harvested on day 19 with
anti-GPIIIa antibody are shown in Fig. 5. Promyelo-
cytic leukemia cells HL60 were used as a negative
 .control Fig. 5A , and megakaryoblastic leukemia
DAMI cells previously shown to express GPIIIa, ref.
.17, Fig. 5B were used as a positive control in this
experiment. The results show that only very few cells
from the progenitor cultures express GPIIIa in the
 .absence of PMA Fig. 5C , whereas a considerable
number of cells express GPIIIa in the presence of
 .PMA Fig. 5D . Interestingly, the cells positive for
GPIIIa in the PMA-containing cultures were often
observed in aggregate clusters; the significance of
this finding is not presently clear.
In summary, the results of the RTrPCR, flow
cytometrical, and immunohistochemical analysis de-
scribed above demonstrate that PMA suppressed ery-
throid, and induced megakaryocytic gene expression
in normal human progenitor cell cultures. The PMA-
mediated inhibition of the erythroid phenotype was
observed under all the experimental conditions tested,
although the extent of this inhibition differed depend-
ing on when PMA was added to the cultures. On the
other hand, the induction of the megakaryocytic phe-
notype was seen only when PMA was added within a
distinct time window.
3.2. Effect of phorbol ester on erythroid and
megakaryocytic gene expression is counteracted by
PKC antagonists
To further investigate a potential role for PKC
signalling in erythroid and megakaryocytic differenti-
ation of hematopoietic progenitor cultures, two spe-
w xcific antagonists of PKC, GF-109203X 37 and Ro-
w x31-8220 38 were employed. These compounds have
been shown to be potent and selective antagonists of
PKC within intact cells. Suspension cultures of
CD34q progenitor enriched populations were ex-
posed to PMA and PKC antagonists on day 11 PKC
.antagonists were added 30 min before PMA , and the
cells analyzed by flow cytometry on day 19 of cul-
ture. The results of a typical experiment reproduced
.three times are shown in Fig. 6. Both GF-109203X
and Ro-31-8220 counteracted the PMA’s negative
effect on erythroid, and positive effect on megakary-
ocytic markers in a dose-dependent manner, although
Ro-31-8220 was more effective than GF-109203X. It
is worth noting that exposure of the progenitor cells
to Ro-31-8220 alone, or to Ro-31-8220 in the pres-
ence of PMA resulted a larger percentage of GPA
positive cells and a higher GPA expression per cell
than in the absence of both PMA and Ro-31-8220.
This enhancement of the erythroid phenotype was
apparent not only from the expression of GPA, but
also from the extent of hemoglobinization of the cell
harvested on day 19: the cell pellets from Ro-31-
8220-containing cultures were dark red whereas those
Fig. 4. Flow cytometric analysis of GPA and CD41 expression by
Epo-containing CD34q progenitor enriched cell populations from
umbilical cord blood, cultured with or without PMA added day
.11 . Cells were harvested on day 19, stained with FITC-con-
jugated anti-GPA and PE-conjugated anti-CD41 antibodies, and
analyzed by flow cytometry as described in Section 2. The
abscissas denote GPA positive cells, and the ordinates, CD41
positive cells.
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Fig. 5. Immunohistochemical analysis of GPIIIa expression by Epo-containing CD34q progenitor enriched cell populations from
 .umbilical cord blood, cultured with or without PMA added day 11 . Cells were harvested on day 19, and reacted with anti-GPIIIa
 .  .antibody as described in Section 2. HL60 cells negative for GPIIIa and DAMI positive for GPIIIa cells were included to test the
 .specificity of the antibody. Original magnification =200 .
from the cultures with Epo alone were significantly
less hemoglobinized. Interestingly, this effect was
observed only when addition of Ro-31-8220 was
 .delayed until days 10–11 not shown .
3.3. Phorbol ester acts directly on erythroid cells.
Analysis of indi˝idual colonies
The experiments shown in Figs. 3–6 were carried
out with cell populations containing, in addition to
erythroid, cells of other hematopoietic lineages.
Therefore, there are several important questions re-
 .garding the interpretation of these experiments: i
does PMA act directly on erythroid cells in suppress-
ing their erythroid phenotype, or through some acces-
 .sory cells secreting an active factor? ii does induc-
tion of the megakaryocytic phenotype in these cul-
tures result from a shift in the differentiation program
of a cell already pursuing a specific differentiation
pathway, or does it result from the activation of
Fig. 6. Flow cytometric analysis of GPA and CD41 expression by Epo-containing CD34q progenitor enriched cell populations from
 .umbilical cord blood, cultured with or without PMA, and with or without PKC antagonists added on day 11 . See legend to Fig. 3 and
Section 2 for other experimental details. The abscissas denote GPA positive cells, and the ordinates, CD41 positive cells. A: yPMA; B:
qPMA; C: q200 nM GF109203X; D: q1 mM GF109203X; E: qPMAq200 nM GF109203X; F: qPMAq1 mM GF109203X; G:
q200 nM Ro-31-8220; H: q1 mM Ro-31-8220; I: qPMAq200 nM Ro-31-8220; J: qPMAq1 mM Ro-31-8220.
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quiescent megakaryocytic progenitors pre-existing in
the cultures prior to addition of PMA?
To address these questions, analysis of transfered
erythroid colonies, and analysis of individual colonies
was carried out, as described below. For the colony
transfer experiments, cultures were established with-
out PMA and incubated for 11 days. On day 11,
easily identifiable immature erythroid colonies were
individually transfered onto fresh methylcellulose
dishes, with one half of the colonies onto a dish with
PMA and one half onto a dish without PMA. The
incubation was then continued until day 20, and the
RTrPCR analysis of the erythroid and megakary-
ocytic mRNAs from the pooled cell populations was
carried out. The results shown in Fig. 7, which
parallel those obtained with the unfractionated cell
 .populations Fig. 3 , indicate that in this system PMA
acts directly rather than through accessory cells. Al-
though we cannot rule out the possibility that some
contaminating accessory cells were co-transferred
with the erythroid cells, it is unlikely that these are
solely responsible for the observed effects, since the
magnitude of the PMA effect in this experiment is
similar to that in the unfractionated cell populations.
Note that g-globin mRNA was induced in this experi-
ment in the presence of PMA; the same effect, al-
Fig. 7. RTrPCR analysis of the mRNAs expressed by cells in
transferred erythroid colonies. On day 11 of culture in the
 .presence of Epo cultures established from PBMC , immature
erythroid colonies were transferred individually into methylcellu-
lose dishes with Epo, with or without PMA. The cell populations
were harvested on day 20, and tested for expression of erythroid
and megakaryocytic mRNAs. E. coli rRNA was used as a
negative control.
Fig. 8. RTrPCR analysis of the mRNAs expressed by cells from
individual colonies. Colonies were isolated from methylcellulose
 .cultures established from PBMC grown with Epo, with or
without PMA. All colonies were harvested on day 20. Each
individual colony was tested for expression of all the mRNAs
shown. Lanes 1, 2-colonies from culture without PMA. Lanes
3–6-colonies from culture with PMA. Lanes 7-negative control,
E. coli rRNA.
though to a smaller degree, is seen in Fig. 3 compare
.  .lanes 3 and 5 . These results suggests that: i cells
within transfered erythroid colonies may undergo a
process of de-differentiation toward more primitive
 w x.  .erythroid state see above; ref. 31 , and ii expres-
sion of megakaryocytic mRNAs takes place in the
population of cells that reside within developing ery-
throid colonies. These results do not provide informa-
tion on whether induction of g-globin and megakary-
ocytic mRNAs takes place within the same cell.
Single-cell analysis will be necessary to answer that
question.
To examine the phenotypes of the individual ery-
throid colonies that developed in the absence of
PMA, and those that developed from the immature
erythroid colonies after addition of PMA on day 11,
the colonies were plucked on day 20 from the meth-
ylcellulose cultures, and RNA from each colony was
prepared and tested for expression of b-globin, GPI-
IIa, and RPL19 mRNAs using RTrPCR. Also, ex-
pression of a myeloid mRNA, myeloperoxidase
 w x.MYP, ref. 39 by the cells in the same colonies was
 .determined. The results of this experiment Fig. 8
show that cells that matured in the absence of PMA
 .lanes 1 and 2 expressed high levels of b-globin
mRNA and did not express GPIIIa mRNA. However,
cells that matured in the presence of PMA lanes 3
.through 6 down-regulated their b-globin mRNA and
initiated expression of GPIIIa mRNA. None of these
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cells expressed MYP mRNA a weak unspecific sig-
nal is seen in every lane including the E. coli rRNA,
.a negative control lane . Overall, these results, which
parallel those obtained with the cell populations con-
 .taining other lineages Fig. 3 , support the results of
 .the colony transfer experiments Fig. 7 in suggesting
that in the present system the observed megakary-
ocyte-specific signal originates from the erythroid
colonies, and that, in the presence of PMA, at least
some of the early erythroid cells within these colonies
may undergo a modification of the differentiation
program.
3.4. Phorbol ester dramatically arrests cell prolifera-
tion
In view of two possible modes of PMA action —
modification of a differentiation program vs selective
stimulation of quiescent megakaryocytic progenitor
 .see above — it was important to determine the
effect of PMA on cell proliferation. The rational
behind this is as follows. If PMA stimulates a
megakaryocytic progenitor present as a small fraction
of a starting CD34q progenitor enriched cell popula-
tion which remained quiescent before addition of
.PMA to develop along the megakaryocytic pathway,
one would expect this progenitor to undergo multiple
rounds of cell division after addition of PMA to
generate the number of megakaryocytic cells ob-
 .served Figs. 4 and 6 . On the other hand, if a
modification of a differentiation program of a more
numerous cell population progressing along erythro-
cytic lineage which is already present in the culture
.when PMA is added takes place in this system, this
modification can occur without extensive cell divi-
sion.
In the experiment shown in Fig. 9A reproduced in
w3 xtwo independent experiments, the rate of H thymi-
dine incorporation by the suspension culture cells
grown without PMA was compared to that of the
 .cells grown with PMA added on day 11 . The results
of this experiment demonstrate that addition of PMA
w3 xto the cultures rapidly arrests H thymidine incorpo-
ration. To determine if the PMA induced arrest in
w3 xH thymidine incorporation is also accompanied by
an appreciable cell death, the rate of apoptotic cell
death by the same two types of cultures was com-
pared. As shown in Fig. 9B result reproduced in two
.independent experiments , addition of PMA to the
cultures on day 11, results in about a 2.5-fold in-
crease in cell death over the cell death seen in
untreated cultures.
w3 x  .  .Fig. 9. Analysis of H thymidine uptake A , and apoptosis rate B by cells in Epo-containing suspension cultures in the absence or in
the presence of PMA. Suspension cultures were established using CD34q-enriched cell population from umbilical cord blood. For details
of the experimental procedures see Section 2. The error bars specify values obtained from of the duplicate experiments.
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4. Discussion
The results of this work show that phorbol ester
PMA causes a coordinate down-regulation of ery-
throid and up-regulation of megakaryocytic differen-
tiation programs in cultures of normal human
hematopoietic progenitors. Moreover, these effects of
PMA are reversed by two specific antagonists of
PKC. Therefore, these results strongly suggest that
during normal hematopoiesis a change in PKC activ-
ity may be involved in regulation of both erythroid
and megakaryocytic pathways, albeit in the opposite
directions.
PKC-dependent signalling has previously been im-
plicated in the regulation of both erythroid and
megakaryocytic differentiation of human ery-
throleukemic cell lines. For example, in K562 and
HEL cells, PMA-mediated megakaryocytic differenti-
ation was shown to be accompanied by distinct pat-
terns of activation and changes in the subcellular
w xlocalization of different isotypes of PKC 40,41 .
Also, it has been shown recently that the PKC antag-
onist GF109203X suppresses PMA-mediated
megakaryocytic and stimulates hemin-mediated ery-
w xthroid differentiation of HEL cells 42 . Our results
with normal cells and GF109203X, and another PKC
 .antagonist, Ro-31-8220 Fig. 6 , parallel these results
obtained with HEL cells. The functional importance
of PKC in erythroid and megakaryocytic differentia-
tion has been emphasized by selective over-expres-
sion of the specific isotypes of PKC in K562 cells
w xwith resultant megakaryocytic differentiation 43 . Al-
though the existing data on the role PKC in erythroid
and megakaryocytic differentiation of leukemic cell
lines is compelling, the present work, to our knowl-
edge, provides the first evidence that PKC-dependent
signalling may also be involved in regulation of both
erythroid and megakaryocytic differentiation of nor-
mal human hematopoietic cells.
The finding that exposure of progenitor cultures to
PMA results in the activation of megakaryocyte-
specific genes only when PMA addition is delayed
suggests that a cell population at a relatively ad-
vanced stages of differentiation, possibly even a pop-
ulation of cells already progressing toward the ery-
throid lineage, is targeted by PMA in our system.
This hypothesis is also supported by the colony trans-
fer experiments and by the analysis of the individual
colonies. Because we can not completely rule out a
possibility that a small number of quiescent
megakaryocytic progenitor cells are present in the
immature erythroid colonies before addition of PMA,
single cell assays will be necessary to directly sub-
stantiate this hypothesis. However, the possibility that
only quiescent megakaryocytic progenitor cells within
the immature erythroid colonies are solely responsi-
ble for the observed megakaryocytic phenotype in the
presence of PMA appears unlikely, since the magni-
tude of the PMA effect with individual and trans-
ferred colonies is similar to that in the unfractionated
 .cell populations compare Figs. 3, 7 and 8 . Also,
considering that addition of PMA to these cultures
results in a very rapid halt in all cell proliferation
 .Fig. 9A it is difficult to envision how a limited
number of quiescent megakaryocytic progenitors
could give rise to substantial CD41q, and GPIIIaq
cell populations in the PMA-containing cultures in a
 .period from day 11 to day 19–20 Figs. 4 and 5 .
On the basis of the increase in the apoptotic cell
 .death in the presence of PMA Fig. 9B , it could not
be completely ruled out that the PMA-mediated in-
duction of megakaryocytic phenotype may also be at
least partially explained by the ability of PMA to
selectively promote survival of megakaryocytic cells
and to inhibit survival of erythroid cells. However, in
light of the findings that PMA causes cessation in
cell division, and that in the absence of PMA, expres-
sion of megakaryocytic genes is minimal, this differ-
ential effect on survival of erythroid and megakary-
ocytic cells is unlikely to be solely responsible for the
observed megakaryocytic gene expression of the cell
populations in the presence of PMA.
In hematopoiesis it is generally assumed that once
the cell is committed to a specific pathway of differ-
entiation, this commitment is irreversible. However,
this assumption has been repeatedly challenged in
recent years in a number of different studies. For
example, the data obtained with chicken erythroid
w xcells transformed by E26 avian leukemia virus 44
and with mouse erythroid cells transformed with
w xrafrmyc oncogenes 45 , indicate that under certain
conditions a reversal of the erythroid commitment
accompanied by lineage switching can indeed take
place. In addition to the erythroid, other hemato-
poietic cell lineage switching phenomena have been
w xdescribed 45,46 . Also, it has been shown recently
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that 1,25-dihydroxy vitamin D3 can shift differentia-
tion of normal human neutrophilic promyelocytes
w xtoward monocytermacrophages in vitro 47 . All
these and our results suggest that the process of
lineage commitment in hematopoiesis may not be as
rigid as was previously thought.
A precedent already exists for PKC playing a role
in regulation of differentiation decisions during
hematopoiesis. For example, it has been proposed
that signalling through PKC determines selectivity
between closely related granulocyte and macrophage
 .GM pathways. In human bi-potential promyelocytic
leukemia cell lines, such as HL-60, PMA induces a
dramatic shift toward macrophage differentiation,
whereas granulocytic differentiation is promoted by
w xother inducers that do not activate PKC 48 . PKC
also seems to play a role in normal GM differentia-
tion. Studies of normal murine bi-potential granulo-
cyte macrophage colony-forming cells GM-CFC, ref.
w x.49 found that macrophage colony-stimulating fac-
 .tor M-CSF activates PKC in GM-CFCs, and en-
hances macrophage differentiation; whereas stem cell
 .factor SCF supports granulocytic differentiation in
GM-CFC, and has no effect on PKC activation.
Furthermore, activation of PKC by PMA mimics, and
suppression of PKC by PKC inhibitor, calphostin C,
counteracts the effect of M-CSF on differentiation of
w xthese cells 49 .
Our results, taken together with the results of other
investigators point to a close relationship between
w xerythroid and megakaryocytic pathways 6–17 , and
suggest that PKC-mediated signalling may not only
be important for the development of both erythroid
and megakaryocytic cells, but may also play a role in
the lineage selectivity between erythroid and
megakaryocytic pathways. Other investigators have
shown previously that PMA exerts a negative effect
w xon normal erythroid 50 , and a positive effect on
w xnormal megakaryocytic 51,52 differentiation of
murine progenitor cells in culture. However, these
earlier studies in the murine system, did not address
the question of whether PMA can influence the selec-
tivity between erythroid and megakaryocytic path-
ways in normal cells. Thus our results provide the
first evidence we know of, that PKC-dependent sig-
nalling may be involved in the regulation of differen-
tiation decision between erythroid and megakary-
ocytic pathways in normal human progenitor cells.
Given a known ubiquitous involvement of PKC in
w xa variety of cellular processes 53,54 , a simple onroff
switch of PKC activity is unlikely to represent the
unique signal that specifies commitment between ery-
throid and megakaryocytic pathways. It is more rea-
sonable to suggest that a change in the activity of
specific isotypes of PKC andror a magnitude and a
timing of this change relative to the differentiation
state of the progenitor cell may provide a mechanism
for selectivity between erythroid and megakaryocytic
pathways. Also, because it has been shown that Epo
and Tpo augment the development of both erythroid
w xand megakaryocytic cells 9–11 , one could hypothe-
size that modulation of activity of the specific PKC
isotypes may constitute a part of Epo- andror Tpo-
mediated signalling. Alternatively, ligands other than
Epo and Tpo, may be responsible for PKC activity
modulation during development of erythroid and
megakaryocytic cells. The studies that address these
questions are now in progress.
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